Wegovy and Ozempic are the same molecule — semaglutide, made by Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is FDA-approved for chronic weight management at 2.4 mg weekly (and now 7.2 mg as Wegovy HD). Same drug, different labels, different doses, and wildly different insurance landscapes.
The Dose Gap
Ozempic's maximum approved dose is 2.0 mg. Wegovy's standard dose is 2.4 mg — 20% higher. And Wegovy HD, approved in March 2026, goes to 7.2 mg — more than three times Ozempic's ceiling. The weight loss data from STEP trials was generated at the 2.4 mg dose, meaning the clinical evidence for Wegovy's efficacy simply doesn't apply to Ozempic's lower doses.
Despite this, physicians routinely prescribe Ozempic off-label for weight loss because insurance coverage for diabetes medications is far more established than coverage for obesity medications. Patients may receive Ozempic at 1.0 or 2.0 mg for weight management — doses that produce less weight loss than the 2.4 mg studied in STEP trials.
| Product | Max Dose | Indication | Insurance Coverage |
|---|---|---|---|
| Ozempic | 2.0 mg | Type 2 diabetes | Widely covered under diabetes formularies |
| Wegovy | 2.4 mg / 7.2 mg HD | Chronic weight management | Variable; many plans exclude anti-obesity meds |
| Rybelsus | 14 mg oral | Type 2 diabetes | Covered under diabetes formularies |
| Wegovy Pill | 25 mg oral | Weight management | Limited; new approval Dec 2025 |
The Insurance Game
Here's the core absurdity: obesity is a chronic disease recognized by the AMA, the WHO, and every major medical organization. Yet most insurance plans in the US exclude anti-obesity medications from their formularies while covering the same drug under a diabetes indication. This means a patient with a BMI of 38 and no diabetes may pay $1,300/month for Wegovy, while a patient with a BMI of 28 and type 2 diabetes gets Ozempic for a $25 copay.
The Treat and Reduce Obesity Act, if passed, would require Medicare to cover FDA-approved anti-obesity medications — but as of mid-2026, it hasn't passed. State-level mandates are emerging but inconsistent.
Wegovy and Ozempic are the same molecule at different doses with different regulatory and insurance profiles. If you have type 2 diabetes and want weight loss benefits, Ozempic at 2.0 mg is a reasonable choice with better insurance access. If weight management is your primary goal and you don't have diabetes, Wegovy at 2.4 mg (or HD at 7.2 mg) is the FDA-approved option with stronger efficacy data — but you may face insurance barriers. Compounded semaglutide at telehealth-level pricing bypasses the insurance question entirely, which is why the telehealth market exists.
Injectable semaglutide only. Physician-led, fast onboarding, custom metabolic report. HSA/FSA accepted.
Sema $99/mo, tirz $133/mo. LegitScript, 503A+503B pharmacies. Free consult, free shipping, no membership. Code x7X72r saves $25.
Injectable, oral tirzepatide, microdose. LegitScript. Flat pricing at every dose — no jumps. Commitment plans from $49/mo.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All medications require evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved. Individual results vary.